Mycobacterium tuberculosis ESAT6 CFP10 antigen - AnHui Longcom Biologic Pharmacy

Drug Profile

Mycobacterium tuberculosis ESAT6 CFP10 antigen - AnHui Longcom Biologic Pharmacy

Alternative Names: ESAT6-CFP10; Mycobacterium riyadhense vaccine - AnHui Longcom Biologic Pharmacy; Recombinant EC allergen; TB-PPD

Latest Information Update: 03 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnHui Longcom Biologic Pharmacy
  • Class Antibody diagnostics; Immunotherapies; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 03 Feb 2017 Anhui Zhifei Longcom Biopharmaceutical plans a phase I trial for Tuberculosis (prevention) in China (NCT03026972)
  • 01 Oct 2016 Phase-III clinical trials in Tuberculosis (Diagnosis, In adolescents, In children, In infants, In neonates) in China (Intradermal) (NCT03027154)
  • 01 Oct 2016 Anhui Zhifei Longcom Biopharmaceutical and Jiangsu Provincial Center for Disease Control and prevention completes a phase III trial for Tuberculosis (Diagnosis) in China (Intradermal) (NCT02795260; ChiCTR-IIR-16007904)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top